Innovative Strategies to Combat Antibiotic Resistance: Emerging Trends and Future Directions

Öz

Aim: Antimicrobial resistance (AMR) represents a critical global health challenge exacerbated by the overuse and misuse of antibiotics in human, animal, and environmental contexts. This study aims to examine the barriers to addressing AMR, with a specific focus on scientific, economic, and regulatory challenges in the development and adoption of novel antimicrobial strategies. Methods: This review synthesizes current literature on innovative therapeutic approaches, such as bacteriophage therapy and antimicrobial peptides, alongside an analysis of global policy initiatives, including the WHO Global Action Plan on AMR and the PASTEUR Act. Emphasis is placed on identifying key obstacles and potential solutions within the realms of antibiotic R&D and policy frameworks. Results: Findings highlight the significant promise of alternative therapies and policy-driven incentives to address AMR. However, limitations such as scientific hurdles, economic disincentives, and disparities in regulatory enforcement hinder progress. Novel policy measures like subscription-based models and improved diagnostic tools have shown potential to close existing gaps. Conclusion: Collaborative global efforts are essential to address AMR effectively. Sustainable funding mechanisms, advanced diagnostic technologies, and integrated One Health approaches must be prioritized to bridge gaps between science, policy, and practice. By addressing these challenges, the global community can mitigate the escalating threat of AMR and safeguard the efficacy of antibiotics for future generations. Keywords: antimicrobial resistance, antibiotic development, global health, One Health, policy initiatives

Anahtar Kelimeler

• antibiotic development
• global health
• One Health
• policy initiatives

Antibiyotik Direnciyle Mücadelede Yenilikçi Stratejiler: Yükselen Trendler ve Gelecekteki Yönelimler

Öz

Amaç: Antimikrobiyal direnç (AMR), insan, hayvan ve çevresel bağlamlarda antibiyotiklerin aşırı ve yanlış kullanımıyla daha da kötüleşen kritik bir küresel sağlık sorununu temsil eder. Bu çalışma, yeni antimikrobiyal stratejilerin geliştirilmesi ve benimsenmesindeki bilimsel, ekonomik ve düzenleyici zorluklara özel bir odaklanma ile AMR'yi ele almanın önündeki engelleri incelemeyi amaçlamaktadır. Yöntemler: Bu inceleme, bakteriyofaj tedavisi ve antimikrobiyal peptitler gibi yenilikçi terapötik yaklaşımlar hakkındaki güncel literatürü, WHO AMR Küresel Eylem Planı ve PASTEUR Yasası dahil olmak üzere küresel politika girişimlerinin bir analiziyle birlikte sentezlemektedir. Antibiyotik Ar-Ge ve politika çerçeveleri alanlarındaki temel engelleri ve potansiyel çözümleri belirlemeye vurgu yapılmaktadır. Sonuçlar: Bulgular, AMR'yi ele almak için alternatif tedavilerin ve politika odaklı teşviklerin önemli vaadini vurgulamaktadır. Ancak, bilimsel engeller, ekonomik caydırıcılar ve düzenleyici uygulamadaki eşitsizlikler gibi sınırlamalar ilerlemeyi engellemektedir. Abonelik tabanlı modeller ve geliştirilmiş tanı araçları gibi yeni politika önlemleri, mevcut boşlukları kapatma potansiyeli göstermiştir. Sonuç: AMR'yi etkili bir şekilde ele almak için işbirlikçi küresel çabalar esastır. Sürdürülebilir finansman mekanizmaları, gelişmiş tanı teknolojileri ve entegre Tek Sağlık yaklaşımları, bilim, politika ve uygulama arasındaki boşlukları kapatmak için önceliklendirilmelidir. Bu zorluklarla başa çıkarak, küresel topluluk AMR'nin artan tehdidini azaltabilir ve antibiyotiklerin gelecek nesiller için etkinliğini koruyabilir.

Anahtar Kelimeler

• antimikrobiyal direnç
• antibiyotik gelişimi
• küresel sağlık
• Tek Sağlık
• politika girişimleri

Kaynakça

1. Abdulaziz Alqahtani, Bacteriophage treatment as an alternative therapy for multidrug-resistant bacteria. Saudi Medical Journal Dec 2023, 44 (12) 1222-1231. https://doi.org/10.15537/smj.2023.44.12.20230366
2. Alkan, S., Koseoglu, H., & Cinar, H. (2022). Surveillance of antimicrobial resistance in Turkey: Current status and future directions. Journal of Infection and Public Health, 15(4), 456-464. https://doi.org/10.1016/j.jiph.2022.04.005
3. Allen, R. C., Popat, R., Diggle, S. P., & Brown, S. P. (2014). Targeting virulence: Can we make evolution-proof drugs? Nature Reviews Microbiology, 12(4), 300–308. https://doi.org/10.1038/nrmicro3232
4. Antibiotic resistance threats in the United States; 2013. https://www.cdc. gov/drugresistance/pdf/ar-threats-2013-508.pdf. Accessed September 16, 2019.
5. Barlam, T. F., Cosgrove, S. E., Abbo, L. M., MacDougall, C., Schuetz, A. N., Septimus, E. J., ... & Weber, D. J. (2016). Implementing an antibiotic stewardship program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clinical Infectious Diseases, 62(10), e51–e77. https://doi.org/10.1093/cid/ciw118
6. Baur, D., Gladstone, B. P., Burkert, F., Carrara, E., Foschi, F., Döbele, S., & Tacconelli, E. (2017). Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: A systematic review and meta-analysis. The Lancet Infectious Diseases, 17(9), 990–1001. https://doi.org/10.1016/S1473-3099(17)30325-0
7. Battah, B., & Donadu, M. G. (2024). "Quorum Sensing Inhibitors: An Alternative Strategy to Win the Battle against Multidrug-Resistant (MDR) Bacteria." Molecules, 29(15), 3466. https://doi.org/10.3390/molecules29153466
8. Berendonk, T. U., Manaia, C. M., Merlin, C., Fatta-Kassinos, D., Cytryn, E., Walsh, F., ... & Bürgmann, H. (2015). Tackling antibiotic resistance: the environmental framework. Nature Reviews Microbiology, 13(5), 310-317.

9. Blaskovich, M. A. T. (Ed.). (2020). Antibiotics Special Issue: Challenges and Opportunities in Antibiotic Discovery and Development. ACS Infectious Diseases, 6(6), 1286–1288. doi:10.1021/acsinfecdis.0c00331
10. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, Allen J, Tahirli R, Blakemore R, Rustomjee R, Milovic A, Jones M, O'Brien SM, Persing DH, Ruesch-Gerdes S, Gotuzzo E, Rodrigues C, Alland D, Perkins MD.
11. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010 Sep 9;363(11):1005-15. doi: 10.1056/NEJMoa0907847.
12. Bolsoy, N., & Sevil, Ü. (2006). Sağlık-hastalık ve kültür etkileşimi. Atatürk Üniversitesi Hemşirelik Yüksekokulu Dergisi, Vol. 9(3).
13. Bush, K., & Bradford, P. A. (2020). Epidemiology of β-lactamase-producing pathogens. Clinical Microbiology Reviews, 33(2), e00047-19.
14. Chan, B. K., Turner, P. E., Kim, S., Mojibian, H., Elefteriades, J. A., & Narayan, D. (2018). Phage treatment of an aortic graft infected with Pseudomonas aeruginosa. Evolution, Medicine, and Public Health, 2018(1), 60-66.
15. Chen JS, Ma E, Harrington LB, Da Costa M, Tian X, Palefsky JM, Doudna JA. CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity. Science. 2018 Apr 27;360(6387):436-439. doi: 10.1126/science.aar6245.
16. Chin C.D., Laksanasopin T., Cheung Y.K., Steinmiller D., Linder V., Parsa H., Wang J., Moore H., Rouse R., Umviligihozo G., et al. Microfluidics-based diagnostics of infectious diseases in the developing world. Nat. Med. 2011;17:1015–1019. doi: 10.1038/nm.2408.
17. Chindelevitch, L., Jauneikaite, E., Wheeler, N.E., Allel, K., Ansiri-Asafoakaa, B.Y., Awuah, W.A., Bauer, D.C., Beisken, S., Fan, K., Grant, G., Graz, M., Khalaf, Y., Liyanapathirana, V., Montefusco-Pereira, C., Mugisha, L., Naik, A., Nanono, S., Nguyen, A., Rawson, T., Reddy, K., Ruzante, J.M., Schmider, A., Stocker, R., Unruh, L., Waruingi, D., Graz, H., & van Dongen, M. (2022). Applying data technologies to combat AMR: Current status, challenges, and opportunities on the way forward. arXiv. Erişim tarihi: 26 Ocak 2025, https://arxiv.org/abs/2208.04683
18. Chinemerem Nwobodo D, Ugwu MC, Oliseloke Anie C, Al-Ouqaili MTS, Chinedu Ikem J, Victor Chigozie U, Saki M. Antibiotic resistance: The challenges and some emerging strategies for tackling a global menace. J Clin Lab Anal. 2022 Sep;36(9):e24655. doi: 10.1002/jcla.24655.
19. Cisek, A. A., Dąbrowska, I., Gregorczyk, K. P., & Wyżewski, Z. (2017). Phage therapy in bacterial infections treatment: One hundred years after the discovery of bacteriophages. Current Microbiology, 74(2), 277-283.
20. Czaplewski, L., Bax, R., Clokie, M., Dawson, M., Fairhead, H., Fischetti, V. A., ... & Rex, J. H. (2016). Alternatives to antibiotics—a pipeline portfolio review. The Lancet Infectious Diseases, 16(2), 239–251. https://doi.org/10.1016/S1473-3099(15)00466-1
21. Davey, P., Marwick, C. A., Scott, C. L., Charani, E., McNeill, A., Brown, E., ... & Wilcox, M. H. (2017). Interventions to improve antibiotic prescribing practices for hospital inpatients. Cochrane Database of Systematic Reviews, (2), CD003543. https://doi.org/10.1002/14651858.CD003543.pub4
22. Demirci, M., Yilmaz, E., & Kaya, O. (2021). High prevalence of carbapenem-resistant Klebsiella pneumoniae in Turkish hospitals: A national concern. Clinical Microbiology and Infection, 27(3), 435-439. https://doi.org/10.1016/j.cmi.2021.01.001
23. Didelot, X., Bowden, R., Wilson, D. J., Peto, T. E., & Crook, D. W. (2016). Transforming clinical microbiology with bacterial genome sequencing. Nature Reviews Genetics, 13(9), 601–612. https://doi.org/10.1038/nrg3226
24. Doğan, N., Şensoy, N., Temel, R.F., Küçükköse, F., Akyüz, H., Erdal, Y., Korkmaz, O.S.B., & Sayan, T.S. (2021). Aile sağlığı merkezlerinde çalışan hekimlerin akılcı antibiyotik kullanımı konusunda farkındalıkları ve etki eden faktörler. Kocatepe Tıp Dergisi, Özel Sayı, Vol. 22, 155-160.
25. Dunachie S.J., Day N.P., Dolecek C. The challenges of estimating the human global burden of disease of antimicrobial resistant bacteria. Curr. Opin. Microbiol. 2020;57:95–101. doi: 10.1016/j.mib.2020.09.013
26. Dyar, O. J., Huttner, B., Schouten, J., & Pulcini, C. (2017). What is antimicrobial stewardship? Clinical Microbiology and Infection, 23(11), 793-798. https://doi.org/10.1016/j.cmi.2017.08.026
27. Ellington MJ, Ekelund O, Aarestrup FM, Canton R, Doumith M, Giske C, Grundman H, Hasman H, Holden MTG, Hopkins KL, Iredell J, Kahlmeter G, Köser CU, MacGowan A, Mevius D, Mulvey M, Naas T, Peto T, Rolain JM, Samuelsen Ø, Woodford N. The role of whole genome sequencing in antimicrobial susceptibility testing of bacteria: report from the EUCAST Subcommittee. Clin Microbiol Infect. 2017 Jan;23(1):2-22. doi: 10.1016/j.cmi.2016.11.012.
28. Financial Times. (2023). Mass drug administration and AMR challenges in high-mortality regions. Erişim tarihi: 26 Ocak 2025, https://www.ft.com/content/38bfcbe6-4f7d-4a95-879c-12a988321862
29. Fitchett JR, Altun R. Antimicrobial resistance: opportunity for Europe to establish global leadership. The Lancet Infectious Diseases, 2015 Volume 16, Issue 4, 388 – 389
30. Fleitas Martínez, O., Cardoso, M. H., Ribeiro, S. M., & Franco, O. L. (2019). "Recent Advances in Anti-virulence Therapeutic Strategies With a Focus on Dismantling Bacterial Membrane Microdomains, Toxin Neutralization, Quorum-Sensing Interference, and Biofilm Inhibition." Frontiers in Cellular and Infection Microbiology, 9, 74. https://doi.org/10.3389/fcimb.2019.00074
31. Garvey M. Antimicrobial Peptides Demonstrate Activity against Resistant Bacterial Pathogens. Infect Dis Rep. 2023 Aug 14;15(4):454-469. doi: 10.3390/idr15040046.
32. Hancock, R. E., Haney, E. F., & Gill, E. E. (2016). The immunology of host defence peptides: Beyond antimicrobial activity. Nature Reviews Immunology, 16(5), 321-334.
33. Harun, M.G.D., Sumon, S.A., Hasan, I., Akther, F.M., Islam, M.S., & Anwar, M.M.U. (2024). Barriers, facilitators, perceptions and impact of interventions in implementing antimicrobial stewardship programs in hospitals of low-middle and middle countries: A scoping review. Antimicrobial Resistance & Infection Control, Vol. 13(1), 8. https://doi.org/10.1186/s13756-024-01369-6
34. Iskandar K., Molinier L., Hallit S., Sartelli M., Hardcastle T.C., Haque M., Lugova H., Dhingra S., Sharma P., Islam S., et al. Surveillance of antimicrobial resistance in low- and middle-income countries: A scattered picture. Antimicrob Resist. Infect. Control. 2021;10:1–13. doi: 10.1186/s13756-021-00931
35. İlhan, N., & Akhan, L.U. (2019). Kültürel özelliklerin sağlık üzerine etkileri. İTOBİAD Kongre, II. İnsan ve Toplum Bilimleri Araştırmaları Kongresi.
36. Ji S., An F., Zhang T., Lou M., Guo J., Liu K., Zhu Y., Wu J., Wu R. Antimicrobial peptides: An alternative to traditional antibiotics. Eur J Med Chem. 2024 Feb 5;265:116072. doi: 10.1016/j.ejmech.2023.116072.
37. Simpkin, V., Renwick, M., Kelly, R. Mossialos, E. Incentivising innovation in antibiotic drug discovery and development: progress, challenges and next steps. J Antibiot 70, 1087–1096 (2017). https://doi.org/10.1038/ja.2017.124
38. Kalli, M., Noutsopoulos, C., & Mamais, D. (2023). The fate and occurrence of antibiotic-resistant bacteria and antibiotic resistance genes during advanced wastewater treatment and disinfection: A review. Water, 15(11), 2084. https://doi.org/10.3390/w15112084
39. Kanan, M., Ramadan, M., Haif, H., Abdullah, B., Mubarak, J., Ahmad, W., Mari, S., Hassan, S., Eid, R., Hasan, M., Qahl, M., Assiri, A., Sultan, M., Alrumaih, F., & Alenzi, A. (2023). Empowering low- and middle-income countries to combat AMR by minimal use of antibiotics: A way forward. Antibiotics (Basel), Vol. 12(10), 1504. https://doi.org/10.3390/antibiotics12101504
40. Kong, C., Neoh, H., & Nathan, S. (2016). "Targeting Staphylococcus aureus Toxins: A Potential Form of Anti-Virulence Therapy." Toxins, 8(3), 72. https://doi.org/10.3390/toxins8030072
41. Laxminarayan R., Duse A., Wattal C., Zaidi A.K., Wertheim H.F., Sumpradit N., Vlieghe E., Hara G.L., Gould I.M., Goossens H., Greko C., So A.D., Bigdeli M., Tomson G., Woodhouse W., Ombaka E., Peralta A.Q., Qamar F.N., Mir F., Kariuki S., Bhutta Z.A., Coates A., Bergstrom R., Wright G.D., Brown E.D., Cars O. Antibiotic resistance-the need for global solutions. Lancet Infect Dis. 2013 Dec;13(12):1057-98. doi: 10.1016/S1473-3099(13)70318-9.
42. Lei, J., Sun, L., Huang, S., Zhu, C., Li, P., He, J., ... & Nie, G. (2019). The antimicrobial peptides and their potential clinical applications. American Journal of Translational Research, 11(7), 3919-3931. Retrieved from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738436/
43. Lewis, K. (2020). "The discovery of antibiotics: A historical overview." Clinical Microbiology Reviews, 33(4), e00080-20.
44. Lin J., Du F., Long M, Li P. Limitations of Phage Therapy and Corresponding Optimization Strategies: A Review. Molecules. 2022 Mar 13;27(6):1857. doi: 10.3390/molecules27061857.
45. Liu, Y. Y., Wang, Y., Walsh, T. R., Yi, L. X., Zhang, R., Spencer, J., ... & Shen, J. (2016). Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. The Lancet Infectious Diseases, 16(2), 161-168.
46. Magana, M., Pushpanathan, M., Santos, A. L., Leanse, L., Fernandez, M., Ioannidis, A., ... & Tegos, G. P. (2020). The value of antimicrobial peptides in the age of resistance. The Lancet Infectious Diseases, 20(9), e216-e230. https://doi.org/10.1016/S1473-3099(20)30327-3
47. Martínez, J. L., Coque, T. M., & Baquero, F. (2015). What is a resistance gene? Ranking risk in resistomes. Nature Reviews Microbiology, 13(2), 116-123.
48. Max, R., Rehman, S. (2023). Addressing antimicrobial resistance in low and middle-income countries: Current perspectives and future directions. Environmental Science and Pollution Research, 30, 29434–29445.
49. McCubbin KD, Anholt RM, de Jong E, Ida JA, Nóbrega DB, Kastelic JP, Conly JM, Götte M, McAllister TA, Orsel K, Lewis I, Jackson L, Plastow G, Wieden HJ, McCoy K, Leslie M, Robinson JL, Hardcastle L, Hollis A, Ashbolt NJ, Checkley S, Tyrrell GJ, Buret AG, Rennert-May E, Goddard E, Otto SJG, Barkema HW. Knowledge Gaps in the Understanding of Antimicrobial Resistance in Canada. Front Public Health. 2021 Oct 20;9:726484. doi: 10.3389/fpubh.2021.726484.
50. Michael, I., Rizzo, L., McArdell, C. S., Manaia, C. M., Merlin, C., Schwartz, T., Dagot, C., & Fatta-Kassinos, D. (2013). Urban wastewater treatment plants as hotspots for antibiotic-resistant bacteria and genes spread into the environment: A review. Science of the Total Environment, 447, 345–360. https://doi.org/10.1016/j.scitotenv.2013.01.032 Milmo, S. (2019). Regulating pharmaceuticals in the environment. Pharmaceutical Technology Europe, 31(4), 8–9. Retrieved from https://www.pharmtech.com
51. Murray, C. J. L., Ikuta, K. S., Sharara, F., Swetschinski, L., Aguilar, G. R., Gray, A., ... & Rao, P. (2022). Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet, 399(10325), 629-655. https://doi.org/10.1016/S0140-6736(21)02724-0
52. Mustafa M.I., Makhawi A.M. SHERLOCK and DETECTR: CRISPR-Cas Systems as Potential Rapid Diagnostic Tools for Emerging Infectious Diseases. J Clin Microbiol. 2021 Feb 18;59(3):e00745-20. doi: 10.1128/JCM.00745-20.
53. Nobrega, F. L., Costa, A. R., Kluskens, L. D., & Azeredo, J. (2018). Revisiting phage therapy: New applications for old resources. Trends in Microbiology, 26(8), 688–698. https://doi.org/10.1016/j.tim.2018.01.006
54. Okeke, I. N., Peeling, R. W., Goossens, H., Auckenthaler, R., Olmsted, S. S., de Lavison, J. F., ... & Nordqvist, K. (2011). Diagnostics as essential tools for containing antimicrobial resistance. Drug Resistance Updates, 14(2), 95–106. https://doi.org/10.1016/j.drup.2011.02.002
55. Outterson, K., et al. (2016). "Delinking Investment in Antibiotics from Sales: A Key Component of a Global Solution." Clinical Infectious Diseases, 62(S2), S81-S88.
56. Painter, C., Faradiba, D., Chavarina, K.K., Sari, E.N., Teerawattananon, Y., Aluzaite, K., & Ananthakrishnan, A. (2023). A systematic literature review of economic evaluation studies of interventions impacting antimicrobial resistance. Antimicrobial Resistance & Infection Control, Vol. 12(1), 69. https://doi.org/10.1186/s13756-023-01265-5
57. Panovska, A. P., & Hajrulai-Musliu, Z. (2024). Antibiotic resistance and aquatic systems: Importance in public health. Water, 16(17), 2362. https://doi.org/10.3390/w16172362
58. Piddock, L.J.V., Alimi, Y., Anderson, J. et al. Advancing global antibiotic research, development and access. Nat Med 30, 2432–2443 (2024). https://doi.org/10.1038/s41591-024-03218-w
59. Pirnay, J. P., Verbeken, G., Ceyssens, P. J., Huys, I., De Vos, D., Amadeus, G., ... & Merabishvili, M. (2019). The phage therapy paradigm: Pre-à-Porter or Sur-Mesure? Pharmaceutical Research, 36(4), 117. https://doi.org/10.1007/s11095-019-2617-x
60. Pokharel, S., Raut, S., & Adhikari, B. (2019). Tackling antimicrobial resistance in low-income and middle-income countries. BMJ Global Health, Vol. 4, e002104. https://doi.org/10.1136/bmjgh-2019-002104
61. Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. Pathog Glob Health. 2015;109(7):309. doi:10.1179/2047773215Y.0000000030
62. Rex, J. H., & Outterson, K. (2016). Antibiotic reimbursement in a model delinked from sales: A benchmark-based worldwide approach. The Lancet Infectious Diseases, 16(4), 500-505. https://doi.org/10.1016/S1473-3099(16)00068-2
63. Ribeiro da Cunha B, Fonseca LP, Calado CRC. Antibiotic Discovery: Where Have We Come from, Where Do We Go? Antibiotics (Basel). 2019 Apr 24;8(2):45. doi: 10.3390/antibiotics8020045. PMID: 31022923; PMCID: PMC6627412.
64. Rony, M.K.K., Sharmi, P.D., & Alamgir, H.M. (2023). Addressing antimicrobial resistance in low and middle-income countries: Overcoming challenges and implementing effective strategies. Environmental Science and Pollution Research, Vol. 30, 101896–101902. https://doi.org/10.1007/s11356-023-29434-4
65. Schnall, J., Rajkhowa, A., Ikuta, K., Rao, P., & Moore, C.E. (2019). Surveillance and monitoring of antimicrobial resistance: Limitations and lessons from the GRAM project. BMC Medicine, Vol. 17(1), 176. https://doi.org/10.1186/s12916-019-1412-8
66. Schuts, E. C., Hulscher, M. E., Mouton, J. W., Verduin, C. M., Stuart, J. W., Overdiek, H. W., & Prins, J. M. (2016). Current evidence on hospital antimicrobial stewardship objectives: a systematic review and meta-analysis. The Lancet Infectious Diseases, 16(7), 847-856. https://doi.org/10.1016/S1473-3099(16)00065-7
67. Singh, S., Charani, E., Devi, S., Sharma, A., Edathadathil, F., Kumar, A., Warrier, A., Shareek, P.S., Jaykrishnan, A.V., & Ellangovan, K. (2021). A road-map for addressing antimicrobial resistance in low- and middle-income countries: Lessons learnt from the public-private participation and co-designed antimicrobial stewardship programme in the State of Kerala, India. Antimicrobial Resistance & Infection Control, Vol. 10(1), 32. https://doi.org/10.1186/s13756-020-00873-9
68. Sirwan Khalid Ahmed, Safin Hussein, Karzan Qurbani, Radhwan Hussein Ibrahim, Abdulmalik Fareeq, Kochr Ali Mahmood, Mona Gamal Mohamed, Antimicrobial resistance: Impacts, challenges, and future prospects, Journal of Medicine, Surgery, and Public Health, Volume 2, 2024,100081, ISSN 2949-916X, https://doi.org/10.1016/j.glmed .2024.100081.
69. Smith, A., & Team. (2023). Assessing antibiotic resistance in wastewater treatment. Environmental Science & Technology. Retrieved from USC Viterbi Magazine: https://magazine.viterbi.usc.edu
70. Sun Q, Shen L, Zhang BL, Yu J, Wei F, Sun Y, Chen W, Wang S. Advance on Engineering of Bacteriophages by Synthetic Biology. Infect Drug Resist. 2023 Mar 31;16:1941-1953. doi: 10.2147/IDR.S402962.
71. Turkish Ministry of Health. (2023). Rational Drug Use Action Plan. Available at: https://www.saglik.gov.tr U.S. Food and Drug Administration (FDA). (2020) Limited Population Pathway for Antibacterial and Antifungal Drugs – the LPAD Pathway | FDA
72. Van Belkum, A., Soriaga, L. B., LaFave, M. C., Akella, S., Veyrieras, J. B., Barbu, E. M., ... & Dunne, W. M. (2019). Phylogenetic distribution of CRISPR-Cas systems in antibiotic-resistant Pseudomonas aeruginosa. mBio, 10(4), e01436-19.
73. Van Boeckel, TP, Brower, C., Gilbert, M., Grenfell, B. T., Levin, S. A., Robinson, T. P., ... & Laxminarayan, R. (2017). Global trends in antimicrobial use in food animals. Proceedings of the National Academy of Sciences, 114(18), 9347-9352.
74. Van Boeckel TP, Gandra S, Ashok A, Caudron Q, Grenfell BT, Levin SA, Laxminarayan R. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis. 2014 Aug;14(8):742-750. doi: 10.1016/S1473-3099(14)70780-7.
75. Van Dijck, C., Vlieghe, E., & Cox, J. A. (2018). Antibiotic stewardship interventions in hospitals in low-and middle-income countries: A systematic review. Bulletin of the World Health Organization, 96(4), 266–280. https://doi.org/10.2471/BLT.17.203448
76. Van Santen, K. L., Edwards, J. R., Seibert, D. J., & McDonald, L. C. (2022). "Antimicrobial stewardship programs in hospitals: Implementation and impact." Infection Control & Hospital Epidemiology, 43(3), 239-245. https://doi.org/10.1017/ice.2021.330
77. Ventola, C. L. (2015). "The antibiotic resistance crisis: part 1: causes and threats." P&T, 40(4), 277-283. Verma, D. P., Tripathi, A. K., & Thakur, A. K. (2024). Innovative Strategies and Methodologies in Antimicrobial Peptide Design. Journal of Functional Biomaterials, 15(11), 320. https://doi.org/10.3390/jfb15110320
78. Wernli, Didier & Jørgensen, Peter & Parmley, Elizabeth & Troell, Max & Majowicz, Shannon & Harbarth, Stephan & Léger, Anaïs & Lambraki, Irene & Graells, Tiscar & Henriksson, Patrik & Carson, Carolee & Cousins, Melanie & Ståhlgren, Gunilla & Mohan, Chadag & Simpson, Andrew & Wieland, Barbara & Pedersen, Karl & Schneider, Annegret & Chandy, Sujith & Pittet, Didier. (2020). Evidence for action: a One Health learning platform on interventions to tackle antimicrobial resistance. The Lancet Infectious Diseases. 20. 10.1016/S1473-3099(20)30392-3.
79. Woldegeorgis, B.Z., Kerbo, A.A., Obsa, M.S., & Mokonnon, T.M. (2023). A systematic review and meta-analysis of antimicrobial resistance knowledge, attitudes, and practices: Current evidence to build a strong national antimicrobial drug resistance narrative in Ethiopia. PLoS One, Vol. 18(6), e0287042. https://doi.org/10.1371/journal.pone.0287042
80. World Health Organization (WHO). The Global Action Plan on Antimicrobial Resistance, with an emphasis on a One Health approach. WHO; 2015. Available from: https://www.who.int/publications/i/item/9789241509763 World Health Organization (WHO) (2015). Global Action Plan on Antimicrobial Resistance. Global action plan on antimicrobial resistance
81. World Health Organization (WHO). (2019). "Global Antibiotic Research and Development Partnership (GARDP)." Retrieved from WHO.int.
82. World Health Organization. (2023). Antimicrobial resistance. Erişim tarihi: 21 Kasım 2023, https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance?utm_source=chatgpt.com
83. Zay Ya, K., Lambiris, M.J., Levine, G.A., Tediosi, F., & Fink, G. (2024). Coverage of policies to improve antimicrobial stewardship in human medicine in low and middle-income countries: Results from the Global Survey of Experts on Antimicrobial Resistance. BMC Public Health, Vol. 24(1), 2297. https://doi.org/10.1186/s12889-024-19542-2